Grants

Dates Principal
Investigator(s)
Grant No./
Donor
Title Goal
7/20-6/25 Ralph Mason, PhD 1R01CA244579, NIH/NCI Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancer To develop the application of a novel vascular disrupting agent (VDA) in combination with leading therapies to enhance treatment of renal cell carcinoma (RCC) and improve tumor control.
8/15-7/21

Carlos Arteaga, MD

Ralph Mason, PhD:  Director of Small Animal Imaging Resource

P30 CA142543, NIH/NCI UT Southwestern Cancer Center Support Grant To support the infrastructure for the promotion of interdisciplinary, translational cancer research through the efforts of senior leadership, five scientific research programs, six shared resources, protocol specific research, protocol review and monitoring, planning and evaluation activities, developmental funds, community outreach and engagement, education and training, and administration.

3/20-2/23

Li Zhang, PhD/ Li Liu, PhD

Co-investigator: Ralph Mason, PhD

RP200021, CPRIT Optimizing Therapeutic Strategies Against Lung Cancer Using Multi-Modality Imaging To determine the degree to which CycT (cyclopamine tartrate) and HSP2 (heme-sequestering peptide 2) alleviate tumor hypoxia and normalize tumor vasculature

09/2022 – 06/2025

PI Lippert (UTSW Mason)

CHE-2155170

SOUTHERN METHODIST UNIVERSITY/NSF

1,2-Dioxetanes for Quantitative Chemiluminescence Imaging Undertake chemiluminescent imaging in mice to assess increasingly sophisticated and refined chemiluminescent imaging agents being developed at SMU.

04/2022 – 03/2027

MPI(Mason, Nguyen, Yang)

1R01HL158204-01A1

UNIVERSITY OF TEXAS AT ARLINGTON/NIH

Novel nanoparticles to stimulate therapeutic angiogenesis in peripheral arterial disease Long-term goal is to develop novel degradable dual-modal imaging nanoparticles (DINPs) to precisely deliver therapeutic reagents that provide cell protection and facilitate the formation of blood vessels de novo at ischemic sites while allowing detection of the NP location and monitoring of their therapeutic effectiveness for PAD treatment.

08/31/2021-08/30/2026

PI: Henning CPRIT RP210099 North Texas Multimodal Small Animal Imaging Core Facility The main goal of this proposal is to build a world-class pre-clinical multimodal imaging core facility to support the ongoing and future cancer research of nearly 100 different PIs from several institutions across North Texas. Mason oversees optical imaging.